![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Florent Edouard
After a successful career start in a French Bank (CDC) front office support, Florent left finance business to launch Areks, a consulting and training start-up company based in Paris, New York and Kobe. Working for multiple pharmaceutical companies, Florent and his partners developed the business and successfully completed the company sale to IQVIA, triggering Florent decision to join AstraZeneca where he assumed successively multiple local and global commercial roles, including 4 years in Japan during which he led the Respiratory / GI franchise and achieved market leadership.
In January 2018, Florent decided to embark on a new adventure and joined Grünenthal, as SVP, Head of Global Commercial Excellence, function in which he is driving the implementation of Grünenthal New Commercial Framework and strategy. Florent is also a regular speaker at international Conferences like EyeForPharma and a passionate innovator and patient advocate.
Company:Grunenthal Group
The Grunenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. They are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, Grunenthal is committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grunenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. Altogether, the Grunenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grunenthal products are sold in more than 155 countries and approx. 5,300 employees are working for the Grunenthal Group worldwide. More information: www.grunenthal.com
